GAVIN PUBLISHERS

Journal of Microbiology and Genetics

Asadi S et al. J Vaccines Immunol 2017: J114.

Review Article

Assessment of Genetic Mutations in Genes Alpha-Synuclein (SNCA), Parkin (PRKN), Leucine-Rich Repeat Kinase 2 (LRRK2 or Dardarin), PTEN-Induced Putative Kinase 1 (PINK1), DJ-1 and ATP13A2 Induced Parkinson's Disease (PD) in Patients Tabriz, IRAN

Shahin Asadi1, Mahsa Jamali1, Samaneh Sadeh Dell[2], Ali Nazirzadeh[2]

[1]Department of Molecular Genetics, Young Researchers and Elite Club, Tabriz Branch, Islamic Azad University, Tabriz, Iran

[2]Department of Molecular Biology Genetics, Young Researchers and Elite Club, Tabriz Branch, Islamic Azad University, Tabriz, Iran

[*]**Corresponding author:** Shahin Asadi. Department of Molecular Genetics Young Researchers and Elite Club, Tabriz Branch, Islamic Azad University, Tabriz, Iran Tel: +989379923364; E-mail: shahin.asadi1985@gmail.com

Citation: Asadi S, Jamali M, Dell SS, Nazirzadeh A (2017) Assessment of Genetic Mutations in Genes Alpha-Synuclein (SNCA), Parkin (PRKN), Leucine-Rich Repeat Kinase 2 (LRRK2 or Dardarin), PTEN-Induced Putative Kinase 1 (PINK1), DJ-1 and ATP13A2 Induced Parkinson's Disease (PD) in Patients Tabriz, IRAN. J Vaccines Immunol 2017: J114.

Received Date: 6 February, 2017; **Accepted Date:** 24 February, 2017; **Published Date:** 2 March, 2017

Abstract

In this study we have analyzed 56 people. 26 patients Parkinson's disease (PD) and 30 persons control group. The genes alpha-synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin), PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2 analyzed in terms of genetic mutations made. In this study, people who have genetic mutations were targeted, with nervous disorders, Parkinson's disease (PD). In fact, of all people with Parkinson's disease (PD), 160 Parkinson's disease (PD) had a genetic mutation in the genes alpha-synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin) And 107 Parkinson's disease (PD) had a genetic mutations in PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2 respectively. Any genetic mutations in the target genes control group, did not show.

Key Words: Genetic study; Parkinson's disease (PD); Mutations The genes alpha-synuclein (SNCA); parkin (PRKN); leucine-rich repeat kinase 2 (LRRK2 or dardarin); PTEN-induced putative kinase 1 (PINK1); DJ-1; ATP13A2.

Introduction

Today, neurological disorders, neuromuscular disorders is very important in creating. Including neurological disorders, including Parkinson's disease. Parkinson's disease is a neuromuscular disorder that commonly causes hand tremors and shaking head. Parkinson's disease is caused by genetic mutations, but also epigenetic factors are critical in inducing the disease.

Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. [1] The symptoms generally come on slowly over time. Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking. [1] Thinking and behavioral problems may also occur. Dementia becomes common in the advanced stages of the disease. Depression and anxiety are also common occurring in more than a third of people with PD. [2] Other symptoms include sensory, sleep, and emotional problems. [1,2] The main motor symptoms are collectively called parkinsonism , or a parkinsonian syndrome . [3,4]

The cause of Parkinson's disease is generally unknown, but believed to involve both genetic and environmental factors. Those with a family member affected are more likely to get the disease themselves. [4] There is also an increased risk in people exposed to certain pesticides and among those who have had prior head injuries while

there is a reduced risk in tobacco smokers and those who drink coffee or tea. [4,5] The motor symptoms of the disease result from the death of cells in the substantia nigra, a region of the midbrain. This results in not enough

dopamine in these areas. [1] The reason for this cell death is

poorly understood, but involves the build-up of proteins into Lewy bodies in the neurons. [4] Diagnosis of typical cases is mainly based on symptoms, with tests such as neuroimaging being used to rule out other diseases. [1]

There is no cure for Parkinson's disease. [1] Initial treatment is typically with the antiparkinson medication L-DOPA (levodopa), with dopamine agonists being used once levodopa becomes less effective. As the disease progresses and neurons continue to be lost, these medications become less effective while at the same time they produce a complication marked by involuntary writhing movements. [2] Diet and some forms of rehabilitation have shown some effectiveness at improving symptoms. [6,7] Surgery to place microelectrodes for deep brain stimulation has been used to reduce motor symptoms in severe cases where drugs are ineffective. [1] Evidence for treatments for the non-movement-related symptoms of PD, such as sleep disturbances and emotional problems, is less strong. [4]

In 2013, PD was present in 53 million people and resulted in about 103,000 deaths globally. [8,9] Parkinson's disease typically occurs in people over the age of 60, of which about one percent are affected. [1,10] Males are more often affected than females. [4] When it is seen in people before the age of 40 or 50, it is called young onset PD. [11] The average life expectancy following diagnosis is between 7 and 14 years. [2] The disease is named after the English doctor James Parkinson, who published the first detailed description in An Essay on the Shaking Palsy, in 1817. [12,13] Public awareness campaigns include World Parkinson's Day (on the birthday of James Parkinson, 11 April) and the use of a red tulip as the symbol of the disease. [14] People with parkinsonism who have increased the public's awareness of the condition include actor Michael J. Fox, Olympic cyclist Davis Phinney, and late professional boxer Muhammad Ali. [15-17]



Figure 1: Schematic view of the structure of the cerebral cortex and hippocampus of the human brain.

Materials and Methods:

In this study, 26 patients with Parkinson's disease (PD) and 30 control group were studied. Peripheral blood samples from patients and parents with written permission control was prepared. After separation of serum, using Real Time-PCR technique of tRNA molecules were collected. To isolate Neuroglial cells erythrocytes were precipitated from Hydroxy Ethyl Starch (HES) was used. At this stage, HES solution in ratio of 1to5with the peripheral blood of patients and controls were mixed. After 60 minutes of incubation at room temperature, the supernatant was removed and centrifuged for 14 min at 400 Gera. The cells ediment with PBS (phosphate Buffered saline), pipetajh and slowly soluble carbohydrate ratio of 1to2 onficole (Ficol) was poured in the 480G

was centrifuged for 34 minutes. Mono nuclear Neuroglial cells also are included, has a lower density than ficole and soon which they are based. The remaining erythrocytes has a molecular weight greater than ficole and deposited in test tubes.

The supernatant, which contained the mono nuclear cells was removed, and the 400 Gera was centrifuged for 12 minutes. Finally, the sediment cell, the antibody and Neuroglial cells was added after 34 minutes incubation at 5°C, the cell mixture was passed from pillar LSMACS. Then the cells were washed with PBS and attached to the column LSMACSS pam Stem cell culture medium containing the transcription genes alpha-synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin), PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2 and were kept.

To determine the purity of Neuroglial cells are extracted, flow cytometry was used. For this purpose, approximately 4-5 × 103 Neuroglial cells were transfer red to1.5ml Eppendorf tube and then was centrifuged at 2000 rpm for 7minutes at time. Remove the supernatant culture medium and there maining sediment, 100µl of PBS buffer was added. After adding 5-10µl CD4+ PE monoclonal anti body to the cell suspension for 60 min at 4°C, incubated and read immediately by flow cytometry. For example, rather than control anti body Neuroglial cells PE, IgG1 negative control solution was used.

Total mRNA extraction procedure includes:

1) 1ml solution spilled Qiazolon cells, and slowly and carefully mixed and incubated at room temperature for 5 minutes. Then 200µl chloroform solution to target mix, then transfer the micro tubes were added, and the shaker well was mixed for 15 seconds. The present mix for 4 minutes at room temperature and then incubated for 20 min at 4°C an was centrifuged at 13200 rpm era. Remove the upper phase product were transfer reductase new mi-

crotube and to the one times the volume of cold ethanol was added. The resulting mixture for 24 hours at -20°C were incubated.

2) Then for 45 min at 4°Can was centrifuged at 12000 rpm era. Remove the supernatant and the white precipitate, 1ml of cold 75% ethanol was added to separate the sediment from micro tubes were vortex well. The resulting mixture for 20 min at 4°C an by the time we were centrifuged 12000 rpm. Ethanol and the sediment was removed and placed at room temperature until completely dry deposition. The precipitate was dissolved in 20µl sterile water and at a later stage, the concentration of extracted mRNA was determined.

To assessment the quality of mi-RNAs, the RT-PCR technique was used. The cDNA synthesis in reverse transcription reaction (RT) kit (Fermentas K1622) and 1µl oligo primers 18 (dT) was performed. Following the PCR reaction 2µM dNTP, 1µg cDNA, Fermentas PCR buffer1X, 0 / 75µM MgCl2, 1.25 U / µL Tag DNA at 95°C for 4 min, 95°C for 30s, annealing temperature58°C for 30s, and72°C for30 seconds, 35 cycles were performed. Then1.5% agarose gel, the PCR product was dumped in wells after electrophores is with ethidium bromide staining and color were evaluated.



Figure 2: Schematic view of the pattern formed in the band PARKIN and LRRK2gene in patients with Parkinson's.



Figure 3: Schematic view of the PTEN gene expression in cells with mutated in patients with Parkinson's disease.



Figure 4: Schematic view of pattern formation of the band in the gene SNCA along with a diagram of cells mutated in patients with Parkinson's disease.



Figure 5: schematic diagram of epigenetic pattern with phosphorylation of LRRK2 gene gang of mutant cells in patients with Parkinson's disease.

Discussion and conclusion:

According to the results of sequencing the genome of patients with Parkinson's disease (PD), and the genetic mutations alpha-synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin), PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2.genes found that about 94% of patients with Parkinson's disease (PD), they have this genetic mutations. Patients with Parkinson's disease (PD), unusual and

frightening images in the process of Parkinson's disease (PD), experience. Lot epigenetic factors involved in Parkinson's disease (PD). But the most prominent factor to induce Parkinson's disease (PD), mutations is alphasynuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin), PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2 genes. This genes can induce the birth and can also be induced in the adulthood.

Acknowledgments

Thanks to everyone who helped us in doing this project, very grateful. Patients and their families also accept patients who had very much for your cooperation in this study.

References

1. Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson's disease. J Neurochem 1: 318-324.
2. Kalia LV, Lang AE (2015) Parkinson's disease. Lancet 386: 896-912.
3. Barranco Quintana JL, Allam MF, Del Castillo AS, Navajas RF (2009). Parkinson's disease and tea: a quantitative review. J Am Coll Nutr 28: 1-6.
4. Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386: 743-800.
5. Shulman JM, De Jager PL, Feany MB (2011) Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol. 6: 193-222.
6. Schrag A (2007) Epidemiology of movement disorders. In Tolosa E, Jankovic JJ. Parkinson's disease and movement disorders. Hagerstown, Maryland: Lippincott Williams & Wilkins 50-66.
7. Barnett-Cowan M, Dyde RT, Foxe SH, Moro E, Hutchison WD, et al. (2010) Multisensory determinants of orientation perception in Parkinson's disease. Neuroscience 167: 1138-1150.
8. Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol. 59: 449-458.
9. Aarsland D, Londos E, Ballard C (2009) Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. Int Psychogeriatr 21: 216-219.
10. Charcot, Jean-Martin; Sigerson, George (1879) Lectures on the diseases of the nervous system (Second ed), Philadelphia: Henry C. Lea, The strokes forming the letters are very irregular and sinuous, whilst the irregularities and sinuosities are of a very limited width. (...) the down-strokes are all, with the exception of the first letter, made with comparative firmness and are, in fact, nearly normal - the finer upstrokes, on the contrary, are all tremulous in appearance (...) 113.
11. Conn PM (2008) Neuroscience in medicine. Cooper G, Eichhorn G, Rodnitzky RL Parkinson's disease. Totowa, NJ: Humana Press 508-512.
12. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, et al (2009) Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 8: 1128-1139.
13. Fung VS, Thompson PD (2007) Rigidity and spasticity. In Tolosa E, Jankovic. Parkinson's disease and movement disorders. Hagerstown, MD: Lippincott Williams & Wilkins 504-513.
14. Yao SC, Hart AD, Terzella MJ (2013) An evidence-based osteopathic approach to Parkinson disease. Osteopathic Family Physician 5: 96-101.
15. Murray ED, Buttner EA, Price BH (2012) Depression and Psychosis in Neurological Practice . (6th ed.) In Bradley WG, Daroff RB, Fenichel GM, Jankovic J Bradley's Neurology in Clinical Practice: Expert Consult - Online and Print, 6e (Bradley, Neurology in Clinical Practice e-dition 2v Set). 102-103.
16. Hughes JR (2009) Absence seizures: a review of recent reports with new concepts. Epilepsy Behav 15: 404-412.
17. Bradley, Walter G (2012) 67. Bradley's neurology in clinical practice. (6th ed), Elsevier/Saunders, PA, Philadelphia.